BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

4baseCare partners with Caritas Hospitals to bring personalised cancer care to Kerala

04 February 2026 | News

Building a bridge between clinical research and real-world application



Caritas Hospitals, in partnership with Bengaluru-based startup 4baseCare, now brings personalised cancer care to patients in Kottayam and neighbouring regions. Through this collaboration, doctors can use genetic testing to better understand each patient's cancer and choose treatments that are more targeted, effective, and easier for patients to manage, helping reduce unnecessary side effects and improve quality of life.

As part of this partnership, 4baseCare and Caritas will offer personalised, data-driven cancer care closer to patients in the region. Furthermore, the lab will also expand access to genomic testing and targeted therapies in Kerala, building a bridge between clinical research and real-world application.

Commenting on this, Rev Dr Binu Kunnath, Director & CEO Caritas Hospital , said, "At Caritas Hospitals, our focus has always been on delivering care that is compassionate, credible, and clinically advanced. This partnership with 4baseCare strengthens our ability to offer patients truly personalized cancer care, guided by science, driven by data, and delivered with empathy. By integrating advanced genomics into everyday clinical practice, we are not only improving treatment precision, but also expanding access to modern cancer care for patients across the region. This collaboration reflects our long-term commitment to building a healthcare ecosystem where innovation directly translates into better outcomes for patients and families."

Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, "The launch of advanced genomics and precision oncology capabilities at Caritas Hospitals represents yet another step forward in strengthening patient-centric cancer care in India. By bringing cutting-edge genomic technologies to clinical practice, this collaboration moves us closer to a future where every cancer patient can receive treatment that is timely, targeted, and tailored to their individual disease biology."